76
Participants
Start Date
May 7, 2020
Primary Completion Date
September 15, 2020
Study Completion Date
September 15, 2020
IVIG
Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
"Site 06 - Vinnytsia City Clinical Hospital №1", Vinnitsia
"Site 09 - Volyn Regional Clinical Hospital", Lutsk
"Site 07 - Ternopil City Municipal Ambulance Hospital", Ternopil
"Site 04 - City Clinical Infectious Diseases Hospital, Odesa", Odesa
"Site 08 - Central City Clinical Hospital of Ivano-Frankivsk City Council", Ivano-Frankivsk
"Site 03 - Lviv Regional Infectious Diseases Clinical Hospital", Lviv
"Site 02 - Bila Tserkva City Hospital №3", Bila Tserkva
"Site 01 - Kyiv City Clinical Hospital №17", Kyiv
"Site 05 - Kyiv City Clinical Hospital №4", Kyiv
Lead Sponsor
Lviv National Medical University
OTHER
Vinnitsa National Medical University
OTHER
Biopharma Plasma LLC
INDUSTRY